Affiliations 

  • 1 Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France. Electronic address: shahr@iarc.who.int
  • 2 Centre for Clinical Epidemiology, Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Malaysia
  • 3 Department of Surgery, Queen's University, Kingston, Ontario, Canada
  • 4 The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
  • 5 Cancer Epidemiology and Prevention Team, Public Health Expertise, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg
  • 6 Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
  • 7 Queen's University Belfast, United Kingdom
  • 8 Cancer Screening Unit, Institut Català d'Oncologia (ICO), Early Detection of Cancer Group, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain
  • 9 Assam Cancer Care Foundation, Assam, India; PAY-W Clinic, Odisha, India
  • 10 University of Nigeria Teaching Hospital, Enugu, Nigeria
  • 11 King's College London, Institute of Cancer Policy, Guy's Hospital, London, UK
  • 12 Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland
  • 13 Center for Global Health, National Cancer Institute, USA
  • 14 WHO Barcelona Office for Health Systems Financing, World Health Organization Regional Office for Europe, Barcelona, Spain; London School of Hygiene and Tropical Medicine Faculty of Public Health, London, UK
  • 15 The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia; School of Medicine & Dentistry, Griffith University, Gold Coast, Australia
J Cancer Policy, 2024 Jun 01;41:100486.
PMID: 38830535 DOI: 10.1016/j.jcpo.2024.100486

Abstract

During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.